Intravenous (IV) Solutions for Dehydration in Children With Gastroenteritis

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-06-30

Study Completion Date

2013-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to compare the efficacy and safety of the use of a multiple electrolyte solution to the use of saline for the treatment of moderate to severe dehydration due to acute gastroenteritis (AGE) in children.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study Investigating the Use of Intravenous Fluids With Dextrose for Dehydrated Children

NCT01343758

Gastroenteritis Dehydration

COMPLETED NA

IV Glucose for Dehydration Treatment

NCT01285713

Dehydration

COMPLETED PHASE2

Is Electrolyte Maintenance Solution Required in Low-Risk Children With Gastroenteritis?

NCT01185054

Gastroenteritis

COMPLETED PHASE2

Subcutaneous Rehydration Compared to Intravenous Rehydration

NCT00773175

Dehydration

COMPLETED PHASE4

Safety, Acceptability, and Feasibility of Enterade®

NCT03782272

Stunting Environmental Enteric Dysfunction

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective of this study was to compare the efficacy and safety of the use of Plasma Lyte A to the use of NS for the treatment of moderate to severe dehydration and amelioration of metabolic acidosis due to AGE in children (≥ 6 months to \< 11 years of age) by measuring serum bicarbonate levels.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dehydration Gastroenteritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

multiple electrolyte solution

Subjects were randomized to receive either multiple electrolyte solution or saline. These solutions were administered IV at 10-20 mL/kg until the subject appeared clinically rehydrated as assessed by the clinician. The selected dose for these solutions is considered standard of care when treating clinical dehydration in children and is consistent with product labeling.

Group Type EXPERIMENTAL

multiple electrolyte solution

Intervention Type DRUG

IV multiple electrolyte solution dosed as clinically indicated for rehydration

saline

Subjects were randomized to receive either multiple electrolyte solution or saline. These solutions were administered IV at 10-20 mL/kg until the subject appeared clinically rehydrated as assessed by the clinician. The selected dose for these solutions is considered standard of care when treating clinical dehydration in children and is consistent with product labeling.

Group Type ACTIVE_COMPARATOR

saline

Intervention Type DRUG

IV solutions dosed as clinically indicated for rehydration

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

multiple electrolyte solution

IV multiple electrolyte solution dosed as clinically indicated for rehydration

Intervention Type DRUG

saline

IV solutions dosed as clinically indicated for rehydration

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Plasma Lyte A Injection pH 7.4 (Multiple Electrolytes Injection, Type 1, USP) 0.9% Normal Saline

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. AGE (etiology: viral or other) resulting in presentation to the ED deemed in need of IV rehydration. In the 24 hours prior to presentation, the subject experienced at least 3 episodes of diarrhea (loose and/or watery stools) and/or nonbilious vomiting.
2. Moderate to severe dehydration (as assessed by Gorelick score13 ≥ 4
3. ≥ 6 months to \< 11 years of age.
4. Healthy except for the underlying etiology of AGE.
5. Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved written ICFs and privacy language per national regulations (eg, Health Insurance Portability and Accountability Act \[HIPAA\], Personal Information Protection and Electronic Documents Act \[PIPEDA\]) were obtained from the parent/guardian prior to any study-related procedures.

Exclusion Criteria

1. AGE that did not require IV rehydration per the clinician.
2. Gorelick score ≤ 3
3. Bilious vomiting.
4. Received \> 20 mL/kg IV fluid bolus within the 4 hours prior to study enrollment (ie, Hour -4 to Hour 0).
5. Diarrhea lasting \> 7 days prior to presentation to the ED.
6. Chronic vomiting disorder.
7. Grossly bloody diarrhea.
8. Chronic diarrheal disorder.
9. Known hyponatremia (sodium \< 130 mmol/L \[\< 130 mEq/L\]) within 72 hours prior to enrollment.
10. Known hypernatremia (sodium \> 155 mmol/L \[\> 155 mEq/L\]) within 72 hours prior to enrollment.
11. Known hypokalemia (potassium \< 3.0 mmol/L \[\< 3.0 mEq/L\]) within 72 hours prior to enrollment.
12. Known hyperkalemia (potassium \> 5.5 mmol/L \[\> 5.5 mEq/L\]) within 72 hours prior to enrollment.
13. The use of prohibited medications:

* Antacids within 24 hours prior to presentation to the ED and during the study.
* Anti-diarrhea medication within 24 hours prior to presentation to the ED and during the study.
* The systemic use of corticosteroids/corticotropins was prohibited within 72 hours of enrollment.
14. Chronic health condition affecting the ability to tolerate fluids or those that result in electrolyte abnormalities (eg, chronic renal, cardiac, or pulmonary diagnoses), or abnormalities of sodium or potassium handling (eg, endocrine disorders, medications).
15. Any reason for urgent or emergency hospital admission or ED stays of \> 12 hours within 14 days preceding presentation to the ED.
16. Any medical condition likely to interfere with the subject's ability to fully complete all protocol-specified interventions, the ability to undergo all protocol-specified assessments, or likely to prolong the subject's need for medical attention beyond that required for treatment of dehydration.
17. Participation in a study of any investigational drug or device concomitantly or within 30 days prior to enrollment in this study, including previous enrollment in this study.
18. Subject with a \> 50% expected chance of dying within 6 months, in the Investigator's opinion.
19. Known hypersensitivity to either of the investigational products.
20. Other serious acute or active conditions that, in the Investigator's opinion, precluded participation in this study.

Minimum Eligible Age

6 Months

Maximum Eligible Age

10 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No